Posted by Michael Wonder on 08 Sep 2022
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada
7 September 2022 - The country, with an increasing immunoglobulin usage rate, currently imports about 85% of its immunoglobulin demand for patients in Canada who rely on this lifesaving plasma-protein therapy.
Grifols today announced it has signed a pioneering long-term agreement with Canadian Blood Services, Canada's national blood authority, to greatly increase the country's self-sufficiency in immunoglobulin medicines, essential plasma-protein therapies used to treat a wide range of immunodeficiencies and other medical conditions.
